Adagrasib is a targeted drug for the treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutation. It blocks the growth and spread of diseased cells by inhibiting the activity of KRAS G12C mutant protein. Adagrasib has shown significant efficacy in clinical practice, but its use is also accompanied by some adverse reactions and precautions.
Usage and Dosage of Adagrasib
The recommended dose of Adagrasib is 600mg twice a day, continued until disease progression or unacceptable toxicity occurs. Patients should strictly follow the doctor's instructions during medication, monitor adverse reactions regularly, and adjust the dose according to the doctor's advice.
Dose Adjustment
If adverse reactions occur during Adagrasib treatment, it may be necessary to temporarily interrupt treatment, reduce the dose, or permanently stop the drug. The first dose is reduced to 400mg twice a day; the second dose is reduced to 600mg once a day. If the patient cannot tolerate a dose of 600mg once a day, the drug should be permanently discontinued.
Dose adjustment for special populations
For patients with impaired liver function, the dose of adagrasib may need to be adjusted. Patients with mild to moderate liver impairment should use it with caution and adjust the dose according to the doctor's advice. Patients with severe liver impairment should avoid using adagrasib.
The dosage of adagrasib needs to be adjusted according to the patient's specific situation, especially for patients with liver impairment. The clinical effect of adagrasib is also a concern for many patients. Let's take a look at it together below.
Clinical effect of adagrasib
Adagrasib has shown significant efficacy in the treatment of non-small cell lung lesions with KRAS G12C mutations. It helps patients prolong survival and improve quality of life by inhibiting the activity of KRAS G12C mutant protein, blocking the growth and spread of diseased cells.
Gastrointestinal adverse reactions
Adagrasib may cause gastrointestinal adverse reactions such as nausea, diarrhea, and vomiting. Patients should take supportive care treatment during medication, including antidiarrheal drugs, antiemetic drugs or fluid replacement, and suspend medication, reduce the dose or permanently stop adagrasib depending on the severity.
QTc interval prolongation
Adagrasib may cause QTc interval prolongation and increase the risk of ventricular tachyarrhythmias. Patients should monitor electrocardiograms and electrolyte levels regularly during medication, and suspend medication, reduce the dose or permanently stop adagrasib depending on the severity.
The clinical effect of adagrasib is significant, but patients should pay attention to its possible adverse reactions when using it. Next, we will introduce the mitigation methods of adagrasib's adverse reactions.
Mitigation methods of adagrasib's adverse reactions
Common adverse reactions of adagrasib include musculoskeletal pain and decreased appetite. Patients should monitor these adverse reactions regularly during medication and take appropriate mitigation measures according to the doctor's advice.
Musculoskeletal pain
Adagrasib may cause musculoskeletal pain. Patients should take a proper rest during medication, and can massage or apply hot compresses to relieve pain, while avoiding excessive fatigue. If the pain is severe, you should seek medical attention in time. The doctor may recommend the use of painkillers or adjust the dosage.
Decreased appetite
Adagrasib may cause decreased appetite. Patients should maintain a balanced diet during medication and appropriately increase the intake of high-calorie, high-protein foods. If the appetite decreases severely, you should seek medical attention in time. The doctor may recommend the use of appetite stimulants or adjust the dosage.
Adagrasib is a prescription drug. Patients should strictly follow the doctor's instructions when using it, have regular checkups, prevent possible serious adverse reactions, and communicate with the doctor in time if they feel unwell and receive treatment as soon as possible.
